Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.
Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.